Celltrion, a local bio company, on Monday had its biosimilar for an antibody against arthritis approved.

This is the first time an antibody copy treatment was approved in the world, the company said.

The Korea Food and Drug Administration on Monday authorized “Remsima,” a biosimilar of Janssen’s “Remicade.” The company has conducted clinical trials on a total of 856 patients from 29 countries.

The drug maker said Remsima could replace Remicade for use for rheumatic arthritis, ankylosing spondylitis, psoriasis and other conditions.